AstraZeneca's COVID prevention drug cuts risk of disease in vulnerable patients

AstraZeneca's (AZN.L) COVID-19 prevention therapy reduced the risk of infection in patients with weaker immunity in a late-stage trial, meeting its primary goal, the drugmaker said on Thursday.
The long-acting antibody therapy called sipavibart showed a "statistically significant reduction" in symptomatic COVID-19 cases among immunocompromised patients, the company said.